Under the microscope: Antisense Therapeutics (ASX:ANP) - Mark Diamond, Managing Director and CEO by Morgans Financial Limited published on 2020-05-25T01:21:55Z Morgans Senior Analyst Scott Power, spoke with Mark Diamond the CEO of Antisense Therapeutics (ANP) following the release of the positive Phase 2 Duchenne Muscular Dystrophy clinical trial results. Genre Business
